glp-1 and mcas It's wild—but true: mast cells actually have receptors on them. So yes, using a GLP-1 agonist for mast cell activation syndrome (MCAS) is a thing—and in some cases, it really helps A newly published case series

You can learn more from these weight loss statistics and trends to see the full picture

Coverage for weight loss is a different story: only 13 states cover obesity-indicated GLP-1s as of January 2026, and that number has been shrinking as states face budget pressure

Compounded GLP1s filled a gap during shortages, but as supply stabilizes, regulators are signaling that safety and consistency will outweigh affordability

They highlighted that, fortunately, the absolute increase in risk is quite low given that NAION occurs quite infrequently in the general population

Exploring the role of GLP-1 receptor agonists in Alzheimers disease: a review of preclinical and clinical evidence

Ms recientemente, los investigadores han desarrollado agonistas duales, como la tirzepatida, que actan tanto sobre los receptores de GLP-1 como de GIP